GEN Exclusives

More »

GEN News Highlights

More »
Mar 8, 2012

GenOway to Offer PhenoPro’s Mouse Model Phenotyping Services and Expertise

  • French firms genOway and PhenoPro established a strategic alliance through which genOway will exclusively distribute PhenoPro’s services and expertise in mouse model phenotyping and phenogenomics. Established in 2007, Institut Clinique de la Souris spin-out PhenoPro claims to have one of the most advanced and complete phenotyping platforms, founded on the phenotyping of over 800 genetically modified lines over the last six years.

    GenOway offers customized mouse models for the biopharma, chemical, agrochemical, and food industries, and for academic research. The firm says adding PhenoPro’s platform and expertise for customized phenotyping services will provide a more integrated offering for its clients.

    “We have developed a unique technological platform to provide scientists with the most adapted and innovative genetically modified models,” comments Alexandre Fraichard, genOway CEO. “We made the strategic decision to expand this offer to the phenotyping of created models. PhenoPro was the best potential partner since their technologies are well-recognized by the scientific community and we share the same strategy: to develop the most adapted customer services.”

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?